secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2026-10-02T20:15:14+00:00
Accession:  0001193125-26-412300
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BioAge Labs doses first patient in Phase 2 QUELL-DME trial of oral BGE-102 for DME
--------------------------------------------------------------------------------

- First participant dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema.
- Approximately 180 participants randomized 1:1:1: anti-VEGF plus oral placebo; anti-VEGF plus BGE-102 90 mg daily; sham intravitreal injection plus BGE-102 90 mg daily.
- 12 weeks of once-daily dosing with a four-week follow-up; primary endpoint is change in best-corrected visual acuity at week 12, with retinal and biomarker exploratory endpoints.
- Topline results expected in the second half of 2027, and are expected to inform development strategy in other NLRP3-driven retinal diseases including geographic atrophy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/0001193125-26-412300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-412300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer